Psyence BioMed Positioned as World’s only Licensed Pharmaceutical Grade Ibogaine Supplier at Source
Through its investment in and collaboration with PsyLabs, the Company has established a GMP-compliant, pharmaceutical-grade supply chain
Psyence BioMed Welcomes U.S. Executive Action to Advance Research into Ibogaine
Psyence BioMed Expands Australian Clinical Site Network to Five Sites, Advancing NPX-5–Supported Clinical Activities
Psyence BioMed Expands Australian Clinical Site Network to Five Sites, Advancing NPX-5–Supported Clinical Activities
Psyence BioMed Expands Australian Clinical Site Network to Five Sites, Advancing NPX-5–Supported Clinical Activities
Psyence BioMed Advances Vertically Integrated Pharmaceutical Platform Following PsyLabs Export Milestone
Psyence BioMed reinforces its vertically integrated pharmaceutical platform through its investment in PsyLabs, securing GMP manufacturing, compound supply, and long term commercial infrastructure.
Psyence BioMed Announces Export of GMP-Manufactured Natural Psilocybin (NPX-5) to Australia for Ongoing Phase IIb Clinical Trial
Psyence BioMed Put Option exercised by PsyLabs initiates a $5 million share for share exchange, deepening strategic alignment and reinforcing long term access to pharmaceutical grade psychedelic supply as clinical programs advance.
Psyence BioMed Announces Exercise of Put Option by PsyLabs and Strategic Equity Investment
Psyence BioMed Put Option exercised by PsyLabs initiates a $5 million share for share exchange, deepening strategic alignment and reinforcing long term access to pharmaceutical grade psychedelic supply as clinical programs advance.
Psyence BioMed Announces Results of Annual and Special Meeting of Shareholders
Psyence BioMed Annual and Special Meeting results confirm shareholder approval of directors, auditors and potential share consolidation authority of up to 250 to 1.
Psyence BioMed Approves Put Option Agreement with PsyLabs to Secure Strategic Supply and Strengthen Commercialization Pathway
The Put Option Agreement positions Psyence BioMed for potential significant future equity participation in one of the world's most advanced psychedelic pharmaceutical grade manufacturers, thereby securing predictable and reliable supply of pharmaceutical grade psychedelics, as the pathway to commercialization unfolds.
Psyence BioMed Announces Settlement of Shareholder Litigation
Psyence announced that it has entered into a settlement agreement to resolve a direct shareholder claim made by KAOS Capital Ltd ("KAOS").
Psyence BioMed Announces Effective Date for 1-for-6.25 Reverse Stock Split
Psyence Biomed today announced the effective date of its 1-for-6.25 share consolidation (reverse stock split) of the Company's issued and outstanding common shares.